Lorie Loreman, DO
Pulmonary Disease · Florence, SCNPI 1285612291
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,845 of the $62,414 with a category attached, or 62.2%. 43 manufacturers reported payments, led by GSK at 46.6% of the total. Reporting peaked in 2023 at $25,025 and has fallen 93.0% since, to $1,755 in 2025. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $182.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$29K
- Mylan Specialty L.p.$11K
- Sanofi$6K
- Insmed, Inc.$5K
- Regeneron Healthcare Solutions, Inc.$5K
- AstraZeneca$2K
- plus $4K from 37 others
What the payments were for
- Consulting fees$11,89319%
- Speaking & faculty fees$38,84562%
- Travel & lodging$1,7893%
- Food & beverage$9,74316%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$10,343
- DUPIXENT$9,781
- Arikayce$4,441
- STIOLTO RESPIMAT$1,260
- BREZTRI$475
- AIRSUPRA$348
- Inspire Upper Airway Stimulation System$214
- FLOWTRIEVER CATHETER, S$193
- CT THROMBECTOMY SYSTEM KIT$193
- SYMBICORT$126
- BREZTRI AEROSPHERE$125
- NUCALA$115
- TEZSPIRE$114
- FASENRA$114
- TRELEGY ELLIPTA$106
- Da Vinci Surgical System$102
How this compares
$62,414 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 724 | $586,024 |
| OfevNintedanib Esylate | 34 | $458,065 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 318 | $246,838 |
| Breo ElliptaFluticasone/Vilanterol | 424 | $205,704 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $120,014 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 106 | $66,725 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 71 | $43,511 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $43,455 |
| XareltoRivaroxaban | 47 | $41,130 |
| Dupixent SyringeDupilumab | 11 | $39,660 |
| Spiriva HandihalerTiotropium Bromide | 49 | $36,282 |
| Advair HfaFluticasone Propion/Salmeterol | 82 | $34,893 |
| Spiriva RespimatTiotropium Bromide | 50 | $33,149 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $25,341 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 644 | $22,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $29,076 | $898,9111,351 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,452 | $534,725155 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,738 | $276,578416 claims |
| Grifols USA, LLCProlastin C, Gamunex-C | $222 | $163,46940 claims |
| Johnson & JohnsonXarelto | $36 | $41,13047 claims |
| PfizerEliquis | $25 | $16,86017 claims |
| MerckDulera | $96 | $14,04927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Florence
- Vinod JonaFlorence$78K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
- Jake KriegmdColumbia$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.